Talzenna

Active Ingredient(s): Talazoparib Tosylate
FDA Approved: * October 16, 2018
Pharm Company: * PFIZER INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Talzenna Overview

Talazoparib (trade name Talzenna) is an orally available poly ADP ribose polymerase (PARP) inhibitor developed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations.[1] Talazoparib is similar to the first in class PARP inhibitor, olaparib.[2][3] It was approved in 2018 in the United States and 2019 in Europe for germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.[2]&...

Read more Talzenna Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Talazoparib

Recent Talzenna Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Talazoparib Tosylate
  • Capsule: 0.25mg, 1mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Talzenna: (3 results)

Sorted by National Drug Code
  • 0069-0296 Talzenna .25 mg Oral Capsule by Pfizer Laboratories Div Pfizer Inc
  • 0069-1195 Talzenna 1 mg Oral Capsule by Pfizer Laboratories Div Pfizer Inc
  • 63539-295 Talzenna 1 mg Oral Capsule by U.S. Pharmaceuticals

Other drugs which contain Talazoparib Tosylate or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 22 September 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA